Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

Inclusion Criteria: * Locally advanced or metastatic histologically confirmed clear cell or papillary cell renal carcinoma. * Primary tumor surgically removed. * Stable or progressive disease as defined by RECIST criteria. * Age ≥ 18 years. * At least one prior standard of care therapy (IL-2, IFN-α, or approved kinase inhibitor) * At least four weeks from prior use of standard of care therapy. * Karnofsky performance status ≥ 80%. * Corrected Serum Calcium ≥ 10 g/dL. * Patients on stable doses of bisphosphonates (Fosamax, Actonel, Didrocal) that show subsequent tumor progression may continue on this medication; however patients are not allowed to start bisphosphonates within one month prior to starting trial, or throughout the duration of the trial. * Major surgery or radiation therapy completed ≥ 4 weeks prior to treatment. * Clinically immunocompetent. * Free of clinically apparent autoimmune disease. * Absolute lymphocyte count ≥ 500/μL, Absolute neutrophil count ≥ 1200/μL, Platelet count ≥ 100,000/μl, Hemoglobin ≥ 9mg/dL. * No evidence of active ischemia on Electrocardiogram (ECG) * Women must be either post-menopausal, rendered surgically sterile, or using reliable form of contraceptive. * Able to give informed consent and comply with the protocol. Exclusion Criteria: * Prior treatment with TroVax® * No supplements of complementary medicines/botanicals are permitted during study, except for any combination of the following: multivitamins, selenium, lycopene, soy supplements, Vitamin E. * Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment. * Participation in any other clinical trial within 30 days. * Cerebral metastasis on MRI Scan. * Currently active second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse. * Serious intercurrent infections or nonmalignant medical illnesses which are uncontrolled. * Psychiatric illnesses that would limit compliance with protocol. * A history of psychosis or clinical depression. * Liver function tests (ALT, AST) more than 1.5 X upper limit of normal (ULN). Bilirubin must be within normal limits. * Creatinine ≥ 1.5 X ULN. * Known allergy to egg proteins. * Known allergy to neomycin. * History of allergic response to previous vaccinia vaccinations. * Chronic oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency. * Positive for HIV or Hepatitis B or C. * Clinical indication of reduced cardiac function or an ejection fraction of ≤ 40%. * Pregnancy or lactation * Current chemotherapy, immunotherapy, radiation therapy, or the requirement for radiotherapy. * No investigational or commercial agents or therapies other that those included in the protocol treatment may be administered with the intent to treat malignancy.